50 results on '"Kashii Y"'
Search Results
2. CC-CHEMOKINE RECEPTOR 6 (CCR6)-POSITIVE CD4+ T CELLS ARE ENRICHED IN THE LIVER OF VARIOUS LIVER DISEASES - IMPLICATION OF THE ROLE OF MIP-3α AND CCR6 ON THE RECRUITMENT OF ACTIVATED HELPER T CELLS INTO THE LIVER
- Author
-
Shimizu, Y, Murata, H, Kashii, Y, Okada, K, Higuchi, K, and Watanabe, A
- Published
- 2000
3. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells
- Author
-
Kashii Y, Roberto Giorda, Rb, Herberman, Tl, Whiteside, and Nl, Vujanovic
- Subjects
Cytotoxicity, Immunologic ,Lymphotoxin-beta ,Fas Ligand Protein ,Membrane Glycoproteins ,Transcription, Genetic ,Tumor Necrosis Factor-alpha ,Membrane Proteins ,Apoptosis ,Cytotoxicity Tests, Immunologic ,Ligands ,Killer Cells, Natural ,TNF-Related Apoptosis-Inducing Ligand ,Gene Expression Regulation ,Solubility ,Antigens, CD ,Tumor Cells, Cultured ,Humans ,RNA, Messenger ,CD30 Ligand ,Apoptosis Regulatory Proteins ,Lymphotoxin-alpha ,CD27 Ligand - Abstract
Natural killer cells mediate spontaneously secretory/necrotic killing against rare leukemia cell lines and a nonsecretory/apoptotic killing against a large variety of tumor cell lines. The molecules involved in nonsecretory/apoptotic killing are largely undefined. In the present study, freshly isolated, nonactivated, human NK cells were shown to express TNF, lymphotoxin (LT)-alpha, LT-beta, Fas ligand (L), CD27L, CD30L, OX40L, 4-1BBL, and TNF-related apoptosis-inducing ligand (TRAIL), but not CD40L or nerve growth factor. Complementary receptors were demonstrated to be expressed on the cell surface of solid tumor cell lines susceptible to apoptotic killing mediated by NK cells. Individually applied, antagonists of TNF, LT-alpha1beta2, or FasL fully inhibited NK cell-mediated apoptotic killing of tumor cells. On the other hand, recombinant TNF, LT-alpha1beta2, or FasL applied individually or as pairs were not cytotoxic. In contrast, a mixture of the three ligands mediated significant apoptosis in tumor cells. These findings demonstrate that human NK cells constitutively express several of the TNF family ligands and induce apoptosis in tumor cells by simultaneous engagement of at least three of these cytotoxic molecules.
- Published
- 1999
4. Cell-cycle-dependent regulation of erythropoietin receptor gene
- Author
-
Komatsu N, Kirito K, Kashii Y, Yusuke Furukawa, Kikuchi J, Suwabe N, Yamamoto M, and Miura Y
- Subjects
Models, Genetic ,Gene Expression Regulation, Leukemic ,Cell Cycle ,Granulocyte-Macrophage Colony-Stimulating Factor ,Cell Separation ,Resting Phase, Cell Cycle ,Recombinant Proteins ,Cell Line ,Neoplasm Proteins ,DNA-Binding Proteins ,GATA2 Transcription Factor ,Leukemia, Megakaryoblastic, Acute ,Receptors, Erythropoietin ,Erythroid-Specific DNA-Binding Factors ,Humans ,GATA1 Transcription Factor ,RNA, Messenger ,Erythropoietin ,Cell Division ,Transcription Factors - Abstract
To understand the regulatory mechanism of erythropoietin (EPO) receptor (EPOR) gene expression, the effect of EPO on the steady-state level of EPOR mRNA was examined using the human EPO-dependent cell line UT-7 as a model system. We found that the treatment of UT-7 cells with EPO resulted in a transient decrease of the EPOR mRNA level. This transient downregulation was also induced by stimulation with granulocyte-macrophage colony-stimulating factor (GM-CSF), another stimulator of UT-7 cell growth. These results raised the possibility that EPOR gene expression is in part related to cell growth. Moreover, it was found that EPO-induced downregulation of EPOR mRNA level was preceded by a transient downregulation of GATA-1 mRNA. To examine the relationship between the expression of EPOR, GATA-1, and GATA-2 mRNA levels and the cell cycle, logarithmically growing UT-7 cells were centrifugically fractionated according to the cell-cycle phase. Both EPOR and GATA-1 mRNA levels, but not the GATA-2 mRNA level, concomitantly decreased at the G0/G1 phase and increased at the S and G2/M phases. An electrophoretic mobility shift assay (EMSA) showed that in EPO-stimulated UT-7 cells, the dynamic changes in EPOR gene expression paralleled the GATA-1 DNA-binding activity to the oligonucleotide probe containing a GATA-binding site located at the promoter region of the EPOR gene. These findings suggest that the regulation of EPOR mRNA level is mainly associated with GATA-1 gene expression in UT-7 cells undergoing proliferation, and that these serial events are under the control of, or related to, the cell cycle.
- Published
- 1997
5. GERM CELL TUMORS
- Author
-
Yang, Q.-y., primary, Chen, Z.-p., additional, Hayase, T., additional, Gomi, A., additional, Higaki, A., additional, Kawahara, Y., additional, Kobari, T., additional, Fukuda, T., additional, Kashii, Y., additional, Morimoto, A., additional, Sakatani, T., additional, Momoi, M. Y., additional, Murray, M., additional, Hale, J., additional, Heinemann, K., additional, Saran, F., additional, Calaminus, G., additional, Nicholson, J., additional, Martinez, S., additional, Khakoo, Y., additional, Gilheeney, S., additional, Kramer, K., additional, Wolden, S., additional, Souweidane, M., additional, Dunkel, I., additional, Brichtova, E., additional, Pavelka, Z., additional, Bobekova, A., additional, Magnova, O., additional, Kren, L., additional, Svoboda, T., additional, Sprlakova, A., additional, Slampa, P., additional, Zitterbart, K., additional, Sterba, J., additional, Campen, C. J., additional, Ashby, D., additional, Fisher, P. G., additional, Monje, M., additional, Dagri, J., additional, Torkildson, J., additional, Cheng, J., additional, Wang, R. X., additional, Yock, T., additional, Banerjee, A., additional, Dhall, G., additional, Finlay, J., additional, Yanagisawa, T., additional, Fukuoka, K., additional, Suzuki, T., additional, Kohga, T., additional, Wakiya, K., additional, Adachi, J., additional, Mishima, K., additional, Fujimaki, T., additional, Matsutani, M., additional, Nishikawa, R., additional, Frappaz, D., additional, Kortmann, R. D., additional, Alapetite, C., additional, Garre, M. L., additional, Ricardi, U., additional, Saran, F. H., additional, Czech, T., additional, Walker, R., additional, Koga, T., additional, Legault, G., additional, Allen, J., additional, Geludkova, O., additional, Mushinskaya, M., additional, Kushel, Y., additional, Korshunov, A., additional, Melikyan, A., additional, Shishkina, L., additional, Oserova, V., additional, Oserov, S., additional, Maserkina, N., additional, Borodina, I., additional, Kumirova, E., additional, Boyarchuk, N., additional, Gorbatyh, S., additional, Popova, E., additional, Sherbenko, O., additional, Zelinskaya, N., additional, Shammasov, R., additional, Privalova, L., additional, Chulkov, O., additional, Kosel, Y., additional, Cappellano, A. M., additional, Paiva, P., additional, Cavalheiro, S., additional, Dastoli, P., additional, Seixas, M. T., additional, Silva, N. S., additional, Chan, G. C.-F., additional, Shing, M. M.-K., additional, Yuen, H.-L., additional, Li, R. C.-H., additional, Li, C.-K., additional, Ha, S.-Y., additional, Chen, H.-H., additional, Chang, F.-C., additional, Chen, Y.-W., additional, Wong, T.-T., additional, Yarascavitch, B., additional, Stein, N., additional, Ribeiro, L., additional, Whitton, A., additional, Duckworth, J., additional, Scheinemann, K., additional, Singh, S., additional, Ozerov, S., additional, Gorelyshev, S., additional, Trunin, Y., additional, Kagawa, N., additional, Fujimoto, Y., additional, Hirayama, R., additional, Chiba, Y., additional, Kijima, N., additional, Arita, H., additional, Kinoshita, M., additional, Hashimoto, N., additional, Maruno, M., additional, Yoshimine, T., additional, Guerra, G. P., additional, Oscanoa, M., additional, Cavero, L., additional, Yabar, A., additional, Ugarte, E., additional, Trivedi, M., additional, Tyagi, A., additional, Goodden, J., additional, Chumas, P., additional, Elliott, M., additional, Picton, S., additional, Robison, N., additional, Prabhu, S., additional, Sun, P., additional, Chi, S., additional, Kieran, M., additional, Manley, P., additional, Cohen, L., additional, Goumnerova, L., additional, Smith, E., additional, Scott, M., additional, London, W., additional, and Ullrich, N. J., additional
- Published
- 2012
- Full Text
- View/download PDF
6. The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines
- Author
-
Reichert, T E, primary, Kashii, Y, additional, Stanson, J, additional, Zeevi, A, additional, and Whiteside, T L, additional
- Published
- 1999
- Full Text
- View/download PDF
7. Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.
- Author
-
Rabinowich, H, primary, Reichert, T E, additional, Kashii, Y, additional, Gastman, B R, additional, Bell, M C, additional, and Whiteside, T L, additional
- Published
- 1998
- Full Text
- View/download PDF
8. P-357 Analysis of B-cell clonality in liver-infiltrating lymphocytes in chronic hepatitis
- Author
-
KASHII, Y, primary
- Published
- 1995
- Full Text
- View/download PDF
9. Analysis of T-cell receptor V repertoire in liver-infiltrating lymphocytes in chronic hepatitis C
- Author
-
Kashii, Y., Shimizu, Y., Nambu, S., Minemura, M., Okada, K., Higuchi, K., and Watanabe, A.
- Published
- 1997
- Full Text
- View/download PDF
10. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells
- Author
-
Kashii, Y., Roberto Giorda, Herberman, R. B., Whiteside, T. L., and Vujanovic, N. L.
11. Comparison between saliva and gingival crevicular fluid as an index for liver function
- Author
-
Yamaguchi, M., primary, Kawabata, Y., additional, Kashii, Y., additional, and Osaka, T., additional
- Full Text
- View/download PDF
12. Comparison between saliva and gingival crevicular fluid as an index for liver function.
- Author
-
Yamaguchi, M., Kawabata, Y., Kashii, Y., and Osaka, T.
- Published
- 2002
- Full Text
- View/download PDF
13. P-490 Polymerase chain reaction analysis of hepatitis B virus DNA sequences in hepatocellular carcinomas from patients negative for hepatitis B surface antigen and positive for anti-HCV antibody
- Author
-
Nambu, S, Aiba, N, Nishimori, H, Kashii, Y, Higuchi, K, and Watanabe, A
- Published
- 1995
- Full Text
- View/download PDF
14. P-458 Surface expression of B7 on human liver tumor cells and its modulation by cytokines
- Author
-
Shimizu, Y, Kashii, Y, Tsukishiro, T, Nishimori, H, Minemura, M, Miyamoto, M, Higuchi, K, and Watanabe, A
- Published
- 1995
- Full Text
- View/download PDF
15. P-430 Effect of IL-8 on autocrine growth and production of tumor — Associated substances in human liver tumor cell lines
- Author
-
Miyamoto, M, Shimizu, Y, Kashii, Y, Nambu, S, Higuchi, K, and Watanabe, A
- Published
- 1995
- Full Text
- View/download PDF
16. P-356 Distribution of B7-positive cells in liver tissues of various liver diseases
- Author
-
Shimizu, T, Nishimori, H, Kashii, Y, Tsukishiro, T, Minemura, M, Miyamoto, M, Higuchi, K, and Watanabe, A
- Published
- 1995
- Full Text
- View/download PDF
17. Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals.
- Author
-
Tajiri K, Okada K, Ito H, Kawai K, Kashii Y, Tokimitsu Y, Muraishi N, Murayama A, Hayashi Y, Minemura M, Takahara T, Shimizu Y, and Yasuda I
- Subjects
- Humans, Hepacivirus, Antiviral Agents therapeutic use, Retrospective Studies, Liver Cirrhosis drug therapy, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Hepatitis C complications, Hepatitis C drug therapy, Thrombocytopenia etiology, Thrombocytopenia complications, Leukopenia
- Abstract
Background: Thrombocytopenia due to hypersplenism is a major complication of hepatitis C virus (HCV)-associated cirrhosis. HCV eradication improves these complications in some patients, but the long-term effects of HCV eradication on these complications remain unclear, especially in patients treated with direct acting antivirals (DAAs). The aim was to evaluate long term changes in thrombocytopenia and leucopenia after HCV eradication with DAAs., Methods: The present multicenter study retrospectively evaluated changes over 5 years in thrombocytopenia and leukocytopenia, as well as changes in liver fibrosis markers and spleen size, in 115 patients with HCV-cirrhosis treated with DAAs., Results: Thrombocytopenia and leukocytopenia were improved 4 weeks after DAA administration, with thrombocytopenia show further gradual improvement over the next year. Fib-4 index was markedly reduced 1 year after DAA, followed by subsequent gradual reduction over the next 4 years. Spleen size showed gradual annual reductions, with patients experiencing spleen size reduction characterized at baseline by bilirubinemia., Conclusions: Rapid DAA-associated HCV eradication might lead to rapid disappearance of liver inflammation and bone marrow suppression due to HCV infection. HCV eradication may gradually improve portal hypertension, reducing spleen size., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
18. Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study.
- Author
-
Tajiri K, Tokimitsu Y, Kawai K, Motofuji Y, Shinno E, Kashii Y, Muraishi N, Murayama A, Hayashi Y, Minemura M, Takahara T, Shimizu Y, and Yasuda I
- Subjects
- Humans, Sorafenib therapeutic use, Retrospective Studies, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy
- Abstract
Background/aim: Lenvatinib is a tyrosine kinase inhibitor (TKI) more effective against hepatocellular carcinoma (HCC) than sorafenib, making lenvatinib a first-line treatment option for patients with unresectable HCC. In patients treated with sorafenib, post-progression survival (PPS) rather than progression-free survival (PFS) is essential for overall survival (OS). However, the importance of PPS for OS in patients treated with lenvatinib is uncertain, and optimal treatment after lenvatinib failure has not yet been established., Patients and Methods: The present study investigated the correlations of PFS and PPS with OS in studies of HCC patients treated with lenvatinib by weighted linear regression analysis. Furthermore, the contribution of treatment regimens after lenvatinib failure to OS were evaluated in daily clinical practice., Results: An analysis of 20 studies with 4,054 patients found that PPS had a stronger correlation with OS (r=0.869, p<0.001) than did PFS (r=0.505, p=0.007). Analysis of 79 patients with unresectable HCC treated with first-line lenvatinib showed that subsequent treatment was the most significant contributor to OS. Second-line sorafenib was administered to 25 patients, with late transition to third-line treatment being highest among patients who received second-line treatment., Conclusion: PPS contributes significantly to OS in HCC treatment with TKIs, with multi-sequential treatment being a key determinant of longer OS., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
19. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma.
- Author
-
Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, and Yasuda I
- Abstract
Background: Hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients has a high risk of recurrence. Although eradication of HCV is expected to reduce this risk, the risk in patients with a history of HCC may be high after treatment with direct-acting antivirals (DAAs)., Aim: To determine the risk factors for HCC recurrence in patients with HCV and a history of HCC., Methods: The risk of HCC recurrence in patients with a history of HCC and/or of HCC occurrence in patients without a history of HCC after DAA therapy was retrospectively analyzed in 311 HCV patients treated at our institution and several neighboring hospitals. The frequency and predictors of HCC recurrence/ occurrence after DAA treatment were included in these analyses. The clinical course of HCC before and after DAA treatment was also evaluated., Results: HCV patients with a history of HCC were older and had greater progression of liver fibrosis and diabetes than patients without a history of HCC. Median recurrence-free survival (RFS) was 1092 d in patients with a history of HCC, and post-DAA HCC recurrence/occurrence was observed in 29 patients (53.7%) with and 5 (1.9%) without a history of HCC over 6 years ( P < 0.001). RFS in patients with a history of HCC did not differ significantly before and after DAA treatment. The frequency of HCC recurrence/occurrence in patients with a history of HCC was lower after than before DAA treatment. Multivariate analysis showed that the incidence rate of HCC recurrence/occurrence before DAA treatment was the only independent predictor of HCC recurrence/occurrence after DAA treatment. Liver function was well preserved and clinical course was good in patients with HCC recurrence/occurrence after DAA therapy., Conclusion: DAA therapy in patients infected with HCV is also effective in patients with a history of HCC. Curative treatment for HCC is desirable before DAA therapy. The frequency of HCC recurrence/occurrence before DAA therapy was associated with a significantly increased risk of HCC recurrence after DAA therapy. Careful observation after DAA therapy is required in patients with a history of HCC., Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. [Rhabdomyolysis associated with long-term treatment of esomeprazole].
- Author
-
Nishikawa J, Hosokawa A, Fuchino M, Takatori S, Iwamoto M, Kashii Y, Bando T, Shimizu T, Minemura M, and Sugiyama T
- Subjects
- Aged, Esomeprazole therapeutic use, Esophagitis, Peptic, Gastroesophageal Reflux, Humans, Male, Proton Pump Inhibitors therapeutic use, Rhabdomyolysis chemically induced, Rhabdomyolysis therapy, Treatment Outcome, Esomeprazole adverse effects, Proton Pump Inhibitors adverse effects, Rhabdomyolysis diagnosis
- Abstract
Proton pump inhibitors (PPIs) have been widely used in the treatment of gastroesophageal reflux disease and peptic ulcer disease. Although they have a potent acid suppressive effect and excellent efficacy in acid-related diseases, PPI-induced rhabdomyolysis has been reported. Here, we report the case of a patient with reflux esophagitis who developed rhabdomyolysis after esomeprazole treatment. A 67-year-old man with reflux esophagitis who had started esomeprazole treatment for the preceding 10 months complained of back and limb fatigue and myalgia. His serum creatinine kinase (CK) level was markedly elevated, and CK isozyme exhibited an MM pattern. He was diagnosed with rhabdomyolysis induced by esomeprazole. The cessation of esomeprazole rapidly improved his symptoms, and the serum CK level was normalized within 16 days. PPI-induced rhabdomyolysis is a rare complication. In most cases, PPI-induced rhabdomyolysis occurs within 3 months after starting PPIs. However, rhabdomyolysis occurred at 10 months after starting esomeprazole treatment in our patient. Early diagnosis of PPI-induced rhabdomyolysis is required even in long-term PPI users.
- Published
- 2018
- Full Text
- View/download PDF
21. Persistent fever and weight loss due to an interleukin-6-producing adrenocortical oncocytoma in a girl--review of the literature.
- Author
-
Kawahara Y, Morimoto A, Onoue A, Kashii Y, Fukushima N, and Gunji Y
- Subjects
- Adenoma, Oxyphilic blood, Adrenal Gland Neoplasms blood, Child, Diagnosis, Differential, Female, Humans, Tomography, X-Ray Computed, Adenoma, Oxyphilic diagnostic imaging, Adrenal Gland Neoplasms diagnostic imaging, Fever diagnosis, Interleukin-6 blood, Weight Loss
- Abstract
Unlabelled: Adrenocortical oncocytomas are rarely reported, occur almost exclusively in adults, and are mostly nonfunctional. Here, we report an interleukin-6 (IL-6)-producing adrenocortical oncocytoma in an 11-year-old girl presenting with fever, body weight loss, and increased levels of inflammatory markers and serum IL-6. Imaging studies revealed a 4-cm mass in the left adrenal gland. After complete resection, laboratory findings returned to normal. Histology was consistent with adrenocortical oncocytoma, and the tumor cells stained positive for IL-6., Conclusion: IL-6-producing adrenocortical oncocytoma should be included in the differential diagnosis and imaging studies should be performed in patients presenting with persistent fever of unknown origin and high levels of inflammatory markers.
- Published
- 2014
- Full Text
- View/download PDF
22. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
- Author
-
Kawahara Y, Morimoto A, Hayase T, Kashii Y, Fukuda T, and Momoi MY
- Subjects
- Asparagine metabolism, Child, Preschool, Drug Hypersensitivity blood, Enzyme-Linked Immunosorbent Assay, Escherichia coli immunology, Humans, Male, Antineoplastic Agents immunology, Asparaginase immunology, Desensitization, Immunologic methods, Drug Hypersensitivity immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
A patient with acute lymphoblastic leukemia who was hypersensitive to native Escherichia coli L-asparaginase (L-asp) underwent readministration of the L-asp without serious adverse effects for 11 doses using a desensitization protocol every time. Monitoring of anti-L-asp antibody and L-asp activity levels revealed that the serum L-asp activity was below the effective levels during the administration of first 6 to 7 doses because of extremely high levels of anti-L-asp IgG. Sustained L-asp activity was attained since the eighth dose was administered, when the antibody levels were <5 U/mL. L-asp activity levels in patients with L-asp hypersensitivity should be monitored during the desensitization courses to ensure a sufficient L-asp activity.
- Published
- 2014
- Full Text
- View/download PDF
23. Successful treatment with pulse cyclophosphamide of a steroid-refractory hepatitic variant of liver acute graft-vs.-host disease in a child.
- Author
-
Kawahara Y, Morimoto A, Masuzawa A, Ikeda T, Hayase T, Kashii Y, Nozaki Y, Kanai N, and Momoi MY
- Subjects
- Adolescent, Drug Resistance, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Immunosuppressive Agents therapeutic use, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute therapy, Male, Time Factors, Transplantation Conditioning adverse effects, Transplantation, Homologous, Treatment Outcome, Cyclophosphamide administration & dosage, Graft vs Host Disease therapy, Hepatitis drug therapy, Liver Failure therapy, Liver Failure virology, Steroids adverse effects
- Abstract
A 13-yr-old boy with recurrent acute myeloid leukemia underwent HSCT using cells from an unrelated donor who matched all HLA antigens except one. Forty-two days later, the patient developed a steroid-refractory hepatitic variant of liver GVHD with peak ALT and T.Bil values of 1406 mU/mL and 10.4 mg/dL, respectively. He was successfully treated with pulse Cy (1000 mg/dose × one day) without a change in chimerism being observed or acquiring an infection. All immunosuppressant therapies could be discontinued 12 months after HSCT. Two yr after HSCT, the patient remains in CR without chronic GVHD. This single case report suggests that pulse Cy may be a promising therapy for steroid-refractory GVHD, especially hepatitic GVHD, but needs to be further tested in clinical trials., (© 2012 John Wiley & Sons A/S.)
- Published
- 2012
- Full Text
- View/download PDF
24. A marked decrease in CD4-positive lymphocytes at the onset of hepatitis in a patient with hepatitis-associated aplastic anemia.
- Author
-
Ikeda T, Morimoto A, Nakamura S, Yokoyama K, Hayase T, Oh Y, Kashii Y, Yotsumoto S, Okamoto H, and Y Momoi M
- Subjects
- Acute Disease, Child, Hepatitis, Viral, Human immunology, Humans, Male, Anemia, Aplastic etiology, CD4-Positive T-Lymphocytes immunology, Hepatitis, Viral, Human complications, Lymphopenia etiology, Torque teno virus isolation & purification
- Abstract
A 10-year-old Japanese boy developed acute hepatitis with high levels of serum Torque teno virus DNA and marked lymphocytopenia, especially CD4 T-lymphocytopenia. Although the total lymphocyte counts rose as the patient recovered from hepatitis, this was largely because of a marked rise in CD8 cells. In contrast, CD4 cells recovered poorly, resulting in a further striking fall in the CD4/8 ratio. Two months later, the patient developed hepatitis-associated aplastic anemia. He was successfully treated with immunosuppressive therapy, which normalized the lymphocyte subset proportions. T-cell subsets analysis at the onset of hepatitis might be useful for predicting development of hepatitis-associated aplastic anemia.
- Published
- 2012
- Full Text
- View/download PDF
25. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.
- Author
-
Nakamura S, Morimoto A, Oh Y, Hayase T, Kashii Y, Gunji Y, and Momoi MY
- Subjects
- Blood Coagulation Factor Inhibitors analysis, Blood Coagulation Factors administration & dosage, Blood Coagulation Factors therapeutic use, Child, Preschool, Cost-Benefit Analysis, Factor VIIa administration & dosage, Factor VIIa therapeutic use, Hemophilia A blood, Hemophilia A complications, Hemophilia A drug therapy, Hemorrhage blood, Hemorrhage complications, Hemorrhage drug therapy, Hospitalization, Humans, Joints drug effects, Male, Prothrombin analysis, Recombinant Proteins administration & dosage, Recombinant Proteins economics, Recombinant Proteins therapeutic use, Blood Coagulation Factors economics, Factor VIIa economics, Hemophilia A economics, Hemorrhage economics
- Abstract
Patients with hemophilia and high titers of inhibitors are hard to treat during bleeding events and consequently are more likely to incur high treatment costs and to experience deterioration in quality of life. We report here the case of a boy with hemophilia A and high titers of inhibitors who responded well to prophylactic activated prothrombin complex concentrate (APCC) treatment. Previously, he had to be hospitalized frequently because of painful bleeding of target joints of the knee and ankle. At the age of 4 years and 3 months, APCC prophylaxis at a dose of 60 U/kg, three times a week, was initiated together with on-demand therapy with recombinant factor VIIa. This reduced the frequency and severity of bleeding and ended the need for hospitalization. This, together with a decreased requirement for bypass agents, APCC treatment significantly reduced the cost of treatment for this patient.
- Published
- 2012
- Full Text
- View/download PDF
26. Another promising treatment option for neuroblastoma-associated opsoclonus-myoclonus syndrome by oral high-dose dexamethasone pulse: lymphocyte markers as disease activity.
- Author
-
Oguma M, Morimoto A, Takada A, Kashii Y, Fukuda T, Mori M, Yamagata T, Sugie H, and Momoi MY
- Subjects
- B-Lymphocytes immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Child, Preschool, Humans, Kidney Neoplasms complications, Kidney Neoplasms immunology, Male, Neuroblastoma complications, Neuroblastoma immunology, Opsoclonus-Myoclonus Syndrome etiology, Opsoclonus-Myoclonus Syndrome immunology, Anti-Inflammatory Agents administration & dosage, Biomarkers blood, Dexamethasone administration & dosage, Opsoclonus-Myoclonus Syndrome drug therapy
- Abstract
A one-year-old boy with neuroblastoma (NBoma)-associated opsoclonus-myoclonus syndrome (OMS) was treated by oral high-dose dexamethasone (DEX) pulses (20 mg/m(2)/day of DEX for three consecutive days) every 28 days for 6 months after resection of the tumor. All OMS symptoms improved after the first course of DEX pulse therapy and disappeared after the last course. No adverse effects were observed. Minor deterioration of his developmental quotient was noted 33 months after the onset of the disease. NBoma remission has been maintained since treatment. Before DEX pulse therapy, frequency of T lymphocyte, in particular CD4-positive cell decreased markedly resulted in low CD4/8 ratio in the peripheral blood (PB). The frequency of B lymphocyte increased, especially in cerebrospinal fluid. These aberrant values in PB were reversed by DEX pulse therapy and correlated well with the neurological symptoms. A prospective study that assesses the efficacy of this promising and inexpensive treatment for OMS is warranted., (Copyright © 2011 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
27. Six-year-old girl with primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.
- Author
-
Kikuchi Y, Kashii Y, Gunji Y, Morimoto A, Masuzawa A, Takatsuka Y, Fujita E, Komine M, Ohtsuki M, Matsubara D, Kobayashi C, Sakurai A, Yanase K, Kato K, Koike K, Tsuchida M, and Momoi MY
- Subjects
- Biopsy, CD8-Positive T-Lymphocytes pathology, Child, Diagnosis, Differential, Fatal Outcome, Female, Follow-Up Studies, Humans, Lymphoma, T-Cell, Cutaneous immunology, Severity of Illness Index, Skin Neoplasms immunology, CD8-Positive T-Lymphocytes immunology, Lymphoma, T-Cell, Cutaneous pathology, Skin Neoplasms pathology
- Published
- 2011
- Full Text
- View/download PDF
28. Mesenteric venous thrombosis in a child with type 2 protein S deficiency.
- Author
-
Hayakawa T, Morimoto A, Nozaki Y, Kashii Y, Aihara T, Maeda K, and Momoi MY
- Subjects
- Antiviral Agents therapeutic use, Blood Proteins genetics, Child, Preschool, Female, Humans, Influenza A virus, Influenza, Human complications, Influenza, Human drug therapy, Intestines blood supply, Intestines surgery, Ischemia genetics, Ischemia surgery, Mesenteric Vascular Occlusion surgery, Mutation, Oseltamivir therapeutic use, Protein S, Protein S Deficiency genetics, Venous Thrombosis surgery, Mesenteric Vascular Occlusion genetics, Protein S Deficiency complications, Venous Thrombosis genetics
- Abstract
A 5-year-old girl presented with abdominal pain and bloody stools 2 weeks after suffering from influenza A infection. Enhanced computed tomographic scan showed widespread splanchnic venous thrombosis and small intestine necrosis. She recovered after the necrotic bowel was resected. The patient continues to receive anticoagulant therapy. Thrombophilia screening after the complete resolution consistently showed mildly decreased protein S (PS) activity with normal PS antigen levels. Sequence analysis detected a heterozygous K196E mutation in the PROS1 gene. Type 2 PS deficiency was diagnosed. This is the first report of mesenteric vein thrombosis in a child with a type 2 PS deficiency.
- Published
- 2011
- Full Text
- View/download PDF
29. Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: a case report.
- Author
-
Saito M, Gunji Y, Kashii Y, Odaka J, Yamauchi T, Kanai N, and Momoi MY
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Benzamidines, Cyclophosphamide, Dactinomycin, Drug Resistance, Neoplasm, Guanidines therapeutic use, Hemangioendothelioma physiopathology, Hemangioendothelioma therapy, Humans, Immunohistochemistry, Infant, Interferon-alpha therapeutic use, Magnetic Resonance Imaging, Male, Oleic Acids therapeutic use, Platelet Transfusion, Prednisolone therapeutic use, Prognosis, Sclerosing Solutions therapeutic use, Sclerotherapy, Soft Tissue Neoplasms physiopathology, Soft Tissue Neoplasms therapy, Thrombocytopenia etiology, Thrombocytopenia therapy, Vincristine, Hemangioendothelioma metabolism, Soft Tissue Neoplasms metabolism, Vascular Endothelial Growth Factor Receptor-2 biosynthesis, Vascular Endothelial Growth Factor Receptor-3 biosynthesis
- Abstract
This report describes the case of a 10-month-old boy who was diagnosed to have kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt syndrome (KMS), which is a rare pediatric vascular tumor with a high mortality rate. Although both KHE with KMS were resistant to various therapies, such as oral prednisolone, sclerotherapy, and chemotherapy, repeated radiation therapy with methylprednisolone pulse therapy did reduce the volume of KHE and improved the symptoms of KMS. Unfortunately, a regrowth of KHE with KMS was observed 4 months after the cessation of treatment and the patient thereafter died from an intracranial hemorrhage and Pneumocystis carinii pneumonia, which is a complication related to repetitive radiation and steroid therapy. A histopathologic examination of autopsy specimens confirmed a diagnosis of KHE and immunohistologic staining was positive for vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3. These findings may provide the rationale to further investigate the role of VEGFRs in the pathogenesis of KHE and also to elucidate its prognostic value, along with the application of inhibitors for VEGFRs for the treatment of refractory KHE.
- Published
- 2009
- Full Text
- View/download PDF
30. Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis.
- Author
-
Ohga S, Ohara A, Hibi S, Kojima S, Bessho F, Tsuchiya S, Ohshima Y, Yoshida N, Kashii Y, Nishimura S, Kawakami K, Nishikawa K, and Tsukimoto I
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Japan, Male, Middle Aged, Transplantation, Autologous, Treatment Outcome, Anemia, Aplastic genetics, Anemia, Aplastic therapy, Bone Marrow Transplantation, Chromosome Aberrations, Immunosuppressive Agents therapeutic use
- Abstract
The clinical outcome of childhood aplastic anaemia (AA) with aberrant cytogenetic clones at diagnosis was surveyed. Among 198 children with newly diagnosed AA registered with the AA Committee of the Japanese Society of Paediatric Hematology between 1994 and 1998, cytogenetic studies of bone marrow (BM) cells were completed in 159 patients. Apart from one Robertsonian translocation, seven patients (4.4%) showed clonal chromosomal abnormalities in hypoplastic BM without myelodysplastic features. The patients included six girls and one boy with a median age of 11 years (range 5-14 years). Six patients had del(6), del(5), del(13), del(20), or -7, and one showed add(9). Four patients responded to the first immunosuppressive therapy (IST: cyclosporin A plus anti-thymocyte globulin) and one obtained a spontaneous remission. Cytogenetic abnormalities remained in two patients with an IST response. On the other hand, two patients showed no IST response. One did not respond to repeat IST and died of acute graft-versus-host disease after an unrelated-BM transplant. Another obtained a complete response after a successful BM transplant. No haematological findings at diagnosis predicted the treatment response. No significant morphological changes developed during the course of the illness. A literature review revealed that half of 24 AA patients with chromosomal abnormalities responded to the first IST, and that +6 was the sole predictable marker for IST unresponsiveness. These results suggest that IST can be applied as the initial therapy for AA with cytogenetic abnormalities in the absence of completely matched donors.
- Published
- 2002
- Full Text
- View/download PDF
31. CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver.
- Author
-
Shimizu Y, Murata H, Kashii Y, Hirano K, Kunitani H, Higuchi K, and Watanabe A
- Subjects
- Antigens, CD metabolism, Antigens, Differentiation, T-Lymphocyte metabolism, Apoptosis, Chemokine CCL20, Chemokines, CC genetics, Dendritic Cells metabolism, Flow Cytometry, Humans, Immunohistochemistry, Lectins, C-Type, Ligands, Liver pathology, Liver physiopathology, Macrophage Inflammatory Proteins genetics, Necrosis, Phagocytosis physiology, RNA, Messenger metabolism, Receptors, CCR5 metabolism, Receptors, CCR6, Receptors, CXCR3, Receptors, Chemokine genetics, Receptors, Chemokine metabolism, Reverse Transcriptase Polymerase Chain Reaction, T-Lymphocytes metabolism, Chemokines, CC physiology, Hepatitis pathology, Hepatitis physiopathology, Macrophage Inflammatory Proteins physiology, Receptors, Chemokine physiology
- Abstract
It is not fully understood how antigen-specific or-nonspecific T cells migrate into the liver in various liver diseases. Macrophage inflammatory protein (MIP)-3alpha is a chemokine that is expressed mostly in the liver, and the receptor CCR6 is reported to be expressed on memory T cells. In the present study, we focused on the expression of CCR6 on T cells from peripheral blood (PB) and inflamed liver, and analyzed the involvement of MIP-3alpha and CCR6 in the immunopathogenesis of liver diseases. Intrahepatic T cells showed significantly (P <.0001) higher percentages of CCR6(+)CD4(+) T cells compared with PB, which is significantly (P =.037) correlated with the necroinflammatory response in the liver. Most of intrahepatic CCR6(+)CD4(+) cells were also positive for CCR5, which is known to express on T-helper 1 cells. MIP-3alpha was stained in the cells located near piecemeal necrosis, where dendritic cells (DCs) are often observed, and coculture of activated DCs with apoptotic cells induced MIP-3alpha production from the DCs. These data suggest that MIP-3alpha is produced by periportal DCs and/or macrophages after necroinflammatory response, leading to the recruitment of activated T cells into the liver. This process could be important to augment the local immune response in the livers of various liver diseases. The finding might be important not only for the understanding of immunopathogenesis of liver diseases but also for the therapeutic strategy to control the local immune response in the liver.
- Published
- 2001
- Full Text
- View/download PDF
32. Forkhead family transcription factor FKHRL1 is expressed in human megakaryocytes. Regulation of cell cycling as a downstream molecule of thrombopoietin signaling.
- Author
-
Tanaka M, Kirito K, Kashii Y, Uchida M, Watanabe T, Endo H, Endoh T, Sawada K, Ozawa K, and Komatsu N
- Subjects
- Forkhead Box Protein O1, Forkhead Box Protein O3, Forkhead Transcription Factors, Humans, Phosphatidylinositol 3-Kinases metabolism, Phosphorylation, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-akt, Tumor Cells, Cultured, Cell Cycle, DNA-Binding Proteins metabolism, Megakaryocytes metabolism, Protein Serine-Threonine Kinases, Signal Transduction, Thrombopoietin metabolism, Transcription Factors metabolism
- Abstract
FKHRL1, a member of the Forkhead transcription factor family, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt. This molecule is a mammalian homolog of DAF-16, which plays an important role in the longevity of Caenorhabditis elegans. In this study we found that Akt and FKHRL1 proteins were detectable in highly purified normal human megakaryocytes and that these molecules were actually phosphorylated by thrombopoietin (TPO). To clarify the functional role of FKHRL1 in TPO signaling, we established a tetracycline-inducible system in the human TPO-dependent leukemia cell line UT-7/TPO. Induced expression of active FKHRL1 led to cell cycle arrest at G0/G1 phase in this cell line. These results suggest that FKHRL1 plays an important role in the cell cycle of megakaryocytic cells as one of the downstream target molecules of phosphatidylinositol 3-kinase-Akt, presumably mediated through the activation or inactivation of cell cycle-associated gene(s).
- Published
- 2001
- Full Text
- View/download PDF
33. Induction of E-selectin after partial hepatectomy promotes metastases to liver in mice.
- Author
-
Uotani H, Yamashita I, Nagata T, Kishimoto H, Kashii Y, and Tsukada K
- Subjects
- Animals, Antibodies pharmacology, E-Selectin genetics, E-Selectin immunology, Injections, Intravenous, Liver Neoplasms pathology, Male, Mice, Mice, Inbred BALB C, Neoplasm Transplantation, Portal Vein, Postoperative Period, RNA, Messenger metabolism, Tumor Cells, Cultured, E-Selectin metabolism, Hepatectomy methods, Liver Neoplasms etiology, Liver Neoplasms secondary
- Abstract
Background: The liver is the most frequent site of tumor metastasis. It has been suggested that partial hepatectomy promotes liver metastasis of malignant disease and that expression of E-selectin, a cell adhesion molecule, plays roles in tumor metastasis. However, no reports are available concerning the expression of E-selectin after hepatectomy., Methods: In the present study, we used BALB/c mice subjected to 30% partial hepatectomy after injection of 1 x 10(4) colon 26 cells to determine the effects of partial hepatectomy on tumor metastasis to liver. E-Selectin expression within the liver after partial hepatectomy was evaluated using reverse transcription polymerase chain reaction and Western blotting. In addition, we injected polyclonal antibody to E-selectin into mice in which partial hepatectomy had augmented liver metastasis., Results: Mice subjected to partial hepatectomy had significantly increased numbers of liver metastases (sham operation, 1.5 +/- 2.0, vs partial hepatectomy, 35.5 +/- 19.3; P < 0.001). Expression of E-selectin mRNA within the liver was markedly increased 4 h after partial hepatectomy, but subsequently decreased at 24 h. E-Selectin protein was detected 8 h after hepatectomy, but subsequently decreased at 24 h as measured by Western blotting. Mice subjected to intraperitoneal injection of neutralizing antibody after operation had significantly decreased numbers of liver metastases (phosphate-buffered saline, 20.6 +/- 9.2, P < 0.05, and normal IgG, 18.0 +/- 8.0, P < 0.05, compared with polyclonal antibody to E-selectin, 5.6 +/- 4.8)., Conclusion: Induction of E-selectin by partial hepatectomy promotes hematogenous liver metastasis. Our findings can be applied to surgical treatment of liver tumor to reduce the recurrence of liver metastasis after hepatectomy by inhibiting E-selectin-mediated adhesion using reagents to E-selectin., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
34. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction.
- Author
-
Kashii Y, Uchida M, Kirito K, Tanaka M, Nishijima K, Toshima M, Ando T, Koizumi K, Endoh T, Sawada K, Momoi M, Miura Y, Ozawa K, and Komatsu N
- Subjects
- Enzyme Activation, Forkhead Box Protein O1, Forkhead Box Protein O3, Forkhead Transcription Factors, Humans, Tumor Cells, Cultured, DNA-Binding Proteins metabolism, Erythropoiesis, Erythropoietin metabolism, Erythropoietin pharmacology, Phosphatidylinositol 3-Kinases metabolism, Protein Serine-Threonine Kinases metabolism, Signal Transduction drug effects, Transcription Factors metabolism
- Abstract
The phosphatidylinositol 3-kinase (PI3K) signaling pathway is important for the regulation of a number of cellular responses. Serine/threonine kinase Akt (protein kinase B; PKB) is downstream of PI3K and activated by growth factors. This study found that erythropoietin (EPO) induced tyrosine phosphorylation of Akt in a time- and dose-dependent manner in EPO-dependent human leukemia cell line UT-7/EPO. In vitro kinase assay using histone H2B and glucose synthase kinase as substrates demonstrated that Akt was actually activated by EPO. EPO-induced phosphorylation of Akt was completely blocked by a PI3K-specific inhibitor, LY294002, at 10 micromol/L, indicating that activation of Akt by EPO is dependent on PI3K activity. In addition, overexpression of the constitutively active form of Akt on UT-7/EPO cells partially blocked apoptosis induced by withdrawal of EPO from the culture medium. This finding suggested that the PI3K-Akt activation pathway plays some role in the antiapoptotic effect of EPO. EPO induced phosphorylation of a member of the trancription factor Forkhead family, FKHRL1, at threonine 32 and serine 253 in a dose- and time-dependent manner in UT-7/EPO cells. Moreover, results showed that Akt kinase activated by EPO directly phosphorylated FKHRL1 protein and that FKHRL1 phosphorylation was completely dependent on PI3K activity as is the case for Akt. In conjunction with the evidence that FKHRL1 is expressed in normal human erythroid progenitor cells and erythroblasts, the results suggest that FKHRL1 plays an important role in erythropoiesis as one of the downstream target molecules of PI3K-Akt.
- Published
- 2000
35. Case of transient erythroblastopenia of childhood with transient hypogammaglobulinemia.
- Author
-
Itonaga N, Ohtomo T, Kashii Y, Yamauchi T, and Momoi MY
- Subjects
- Agammaglobulinemia virology, Erythrocyte Count, Humans, Infant, Male, Time Factors, Virus Diseases complications, Agammaglobulinemia blood, Erythroblasts pathology
- Published
- 2000
- Full Text
- View/download PDF
36. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression.
- Author
-
Reichert TE, Nagashima S, Kashii Y, Stanson J, Gao G, Dou QP, and Whiteside TL
- Subjects
- Blotting, Western, Carcinoma genetics, Cells, Cultured, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase Inhibitor p27, Cyclins biosynthesis, Cyclins genetics, Humans, Immunoenzyme Techniques, Interleukin-2 genetics, Interleukin-2 physiology, Jurkat Cells metabolism, Jurkat Cells pathology, Keratinocytes cytology, Keratinocytes metabolism, Microtubule-Associated Proteins biosynthesis, Microtubule-Associated Proteins genetics, Neoplasm Proteins genetics, Neoplasm Proteins physiology, Oligonucleotides, Antisense pharmacology, RNA, Messenger biosynthesis, RNA, Neoplasm biosynthesis, Receptors, Interleukin-2 genetics, Receptors, Interleukin-2 physiology, Reverse Transcriptase Polymerase Chain Reaction, T-Lymphocytes cytology, T-Lymphocytes metabolism, Tumor Cells, Cultured, Carcinoma pathology, Cell Cycle genetics, Cell Cycle Proteins, Gene Expression Regulation, Neoplastic drug effects, Interleukin-2 biosynthesis, Neoplasm Proteins biosynthesis, Receptors, Interleukin-2 biosynthesis, Tumor Suppressor Proteins
- Abstract
Human carcinomas were shown to express mRNA and protein for IL-2R alpha, beta and gamma chains. Recently, human carcinomas were also shown to constitutively express protein and mRNA for IL-2 in vivo and in vitro. Here we report that the expression levels of cytoplasmic IL-2 as well as IL-2Rbeta- and gamma-chain in human carcinoma cells change during the cell cycle progression. Carcinoma cells synchronized in the G2/M phase of the cell cycle expressed significantly more intracytoplasmic IL-2 as well as IL-2Rbeta and gamma proteins than tumor cells in the G0/G1 phase. The level of mRNA for IL-2 was 5-10-fold higher in the M phase than in the G0/G1-phase, as shown by quantitative competitive RT-PCR. Expression of the cyclin-dependent kinase (CDK) inhibitor p27kip1 in these carcinoma cells was found to be high in the G0/G1 phase, nearly absent in the S phase, and it increased again in the G2/M phase of the cell cycle. In synchronized cells, the decrease in p27 expression coincided with high levels of expression of IL-2. Using the IL-2 specific antisense oligonucleotide to block synthesis of endogenous IL-2 in tumor cells, we observed increased levels of p27 as well as p21. The antisense oligonucleotides specific for p27 or p21 blocked expression of these proteins but not of IL-2. Thus, endogenous IL-2 is important in regulating expression of p27 as well as p21 and, therefore, in controlling cell cycle progression of tumor cells, while its own expression remains independent of the CDK inhibitors.
- Published
- 2000
- Full Text
- View/download PDF
37. Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice.
- Author
-
Chikamatsu K, Reichert TE, Kashii Y, Saito T, Kawashiri S, Yamamoto E, and Whiteside TL
- Subjects
- Animals, Body Weight, Carcinoma, Squamous Cell secondary, Disease Progression, Female, Head and Neck Neoplasms pathology, Humans, Immunophenotyping, Lymphatic Metastasis, Mice, Mice, Inbred BALB C, Mice, Nude, Mouth Neoplasms pathology, Mouth Neoplasms therapy, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms therapy, Immunotherapy, Adoptive methods, Killer Cells, Lymphokine-Activated transplantation, T-Lymphocytes, Cytotoxic transplantation
- Abstract
We have previously reported that immune anti-tumor effector cells, both cytotoxic T lymphocytes (CTLs) and IL-2-activated natural killer (A-NK) cells, are effective at eliminating human head-and-neck cancer (HNC) targets in vitro and in vivo in xenograft models. In this study, these 2 types of human effector cell were compared for the ability to prevent the development of lymph node metastases in a metastasis model of human squamous-cell carcinoma of the head and neck (SCCHN) established in nude mice. A tumor cell line, OSC-19, was injected into the floor of the mouth in nude mice, and the tumor grew progressively and metastasized to cervical lymph nodes by day 21. As effector cells, a human HLA-A2-restricted CTL line recognizing a shared antigen on OSC-19 and human non-MHC-restricted A-NK cells were used. Both types of effector cell mediated high levels of lysis against OSC-19 targets in 4-hr (51)Cr-release assays. Administration of human CTLs or A-NK cells and IL-2 to the site of tumor growth in mice with 7-day OSC-19 tumors resulted in significant reduction of the number of lymph node metastases relative to untreated or sham-operated controls or to mice treated with IL-2 without the effector cells. Our results suggest that in a xenograft model of human SCCHN implanted in the oral cavity of nude mice, the development of lymph node metastases can be successfully controlled by adoptive transfer of human SCCHN-specific CTLs or SCCHN-reactive A-NK cells plus IL-2., (Copyright 1999 Wiley-Liss, Inc.)
- Published
- 1999
- Full Text
- View/download PDF
38. Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C.
- Author
-
Murakami J, Shimizu Y, Kashii Y, Kato T, Minemura M, Okada K, Nambu S, Takahara T, Higuchi K, Maeda Y, Kumada T, and Watanabe A
- Subjects
- Adult, Aged, Antigens, CD analysis, B-Lymphocytes pathology, DNA-Binding Proteins analysis, DNA-Binding Proteins genetics, Female, HLA-DR Antigens analysis, Hepatitis C, Chronic pathology, Humans, Immunoglobulin D analysis, Immunoglobulin G analysis, Immunoglobulin M analysis, Immunohistochemistry, Ki-67 Antigen analysis, Liver pathology, Lymph Nodes immunology, Lymph Nodes pathology, Male, Middle Aged, Proto-Oncogene Proteins analysis, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-bcl-6, Transcription Factors analysis, Transcription Factors genetics, B-Lymphocytes immunology, Hepatitis C, Chronic immunology, Liver immunology
- Abstract
Intrahepatic lymphoid follicle (ILF) formation is one of the most characteristic and commonly observed histological features in patients with chronic hepatitis C. However, little is known regarding whether follicles in the liver belong to functional lymphoid tissues, where B cells are activated, differentiated, and proliferated, or if the lymphocytes are merely infiltrated after recruitment from the secondary lymphoid organs. To ascertain this possibility, we examined the expression of markers for B-cell activation, differentiation, and proliferation in ILFs in patients with chronic hepatitis C using surgically resected specimens, and compared them with specimens of perihepatic lymph nodes by an immunohistochemical technique. Germinal center (GC) formation in the ILFs was frequently found in HCV-positive cases. The distribution of immunoglobulin M (IgM)-, IgD-, and IgG-positive cells and the expression patterns of Ki-67, CD23, or bcl-2 and bcl-6 gene products in the follicles with GC formation in the liver of patients with chronic hepatitis C were similar to those of lymph nodes, indicating that B cells are activated, proliferated, and differentiated in the ILFs with GC formation in patients with chronic hepatitis C. Oligoclonal expansion of B cells in the livers with ILFs was confirmed by an analysis of immunoglobulin heavy chain (IgH) gene rearrangement determined by polymerase chain reaction (PCR). These data strongly suggest that ILFs with GC formation, which are frequently found in patients with chronic hepatitis C, may functionally be the same as those found in lymph nodes with respect to B-cell expansion and maturation.
- Published
- 1999
- Full Text
- View/download PDF
39. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells.
- Author
-
Miyamoto M, Shimizu Y, Okada K, Kashii Y, Higuchi K, and Watanabe A
- Subjects
- Antigens, CD biosynthesis, Cell Adhesion drug effects, Cell Division drug effects, Cell Transformation, Neoplastic drug effects, Cytokines metabolism, Endothelium, Vascular cytology, Humans, Interleukin-1 pharmacology, Interleukin-8 antagonists & inhibitors, Interleukin-8 metabolism, Membrane Proteins biosynthesis, Neoplasm Proteins metabolism, Oligonucleotides, Antisense pharmacology, Pancreatic Neoplasms pathology, Receptors, Chemokine biosynthesis, Receptors, Cytokine biosynthesis, Receptors, Interleukin biosynthesis, Receptors, Interleukin-8A, Receptors, Interleukin-8B, Recombinant Proteins pharmacology, Tumor Cells, Cultured metabolism, Umbilical Veins cytology, Interleukin-8 pharmacology, Liver Neoplasms pathology
- Abstract
We have previously reported that human liver cancer cell lines produce interleukin-8 (IL-8) at high levels. Those tumor cells appeared to express two kinds of IL-8 receptor on their surface. In order to analyze the role of IL-8 on the biological characteristics of those tumor cells, we suppressed IL-8 production from human liver (HuH-7 and HuCC-T1) and pancreatic cancer cell lines (HuP-T4) by treatment with IL-8 antisense oligonucleotides. Suppression of IL-8 production resulted not only in inhibition of cell growth, but also in an increase in the concentrations of some tumor-associated substances such as carbohydrate antigen 19-9 (CA19-9) in the medium. These data indicate that IL-8 produced by human liver and pancreatic tumors may act as an autocrine growth factor and may control the production of some tumor-associated substances. Furthermore, surface expression of sialyl-Lewis(a), which is a ligand for ELAM-1 on human umbilical vein endothelial cells (HUVEC), HuCC-T1 and HuP-T4 cells was decreased and the attachment of these tumor cells to HUVEC was inhibited by treatment with IL-8 antisense oligonucleotide. Since the soluble form of CA19-9 (sialyl-Lewis(a)) was shown to inhibit the tumor cell binding to HUVEC, the decrease in release of CA19-9 into the medium and increase in the expression of sialyl-Lewis(a) on the cell surface may suggest that IL-8 production from the tumor cells enhances metastatic potential by augmenting the binding activity of the tumor cells to HUVEC. These data demonstrate that a cytokine produced by tumor cells may function as an autocrine growth factor and affect tumor cell dissemination.
- Published
- 1998
- Full Text
- View/download PDF
40. Thrombopoietin supports in vitro erythroid differentiation via its specific receptor c-Mpl in a human leukemia cell line.
- Author
-
Yamada M, Komatsu N, Kirito K, Kashii Y, Tomizuka H, Okada K, Endo T, Fukumaki Y, Shinjo K, Abe K, and Miura Y
- Subjects
- Binding, Competitive, Calcium-Calmodulin-Dependent Protein Kinases metabolism, Cell Differentiation, DNA-Binding Proteins metabolism, Erythroid-Specific DNA-Binding Factors, G1 Phase drug effects, GATA2 Transcription Factor, Gene Expression drug effects, Hemoglobins metabolism, Humans, Janus Kinase 2, Phosphorylation drug effects, Protein Kinase C metabolism, Protein-Tyrosine Kinases metabolism, Receptors, Cytokine metabolism, Receptors, Erythropoietin metabolism, Receptors, Thrombopoietin, STAT5 Transcription Factor, Signal Transduction, Trans-Activators metabolism, Transcription Factors metabolism, Tumor Cells, Cultured, Erythroid Precursor Cells drug effects, Erythropoiesis drug effects, Milk Proteins, Neoplasm Proteins, Proto-Oncogene Proteins metabolism, Thrombopoietin pharmacology
- Abstract
Thrombopoietin (TPO) acts on megakaryopoiesis and erythropoiesis in vitro and in vivo. We isolated a novel subline, UT-7/GMT, from the human leukemia cell line UT-7/GM (N. Komatsu, et al., Blood, 89: 4021-4033, 1997). A small population of UT-7/GM cells positively stained for hemoglobin (Hb) after a 7-day exposure to TPO. More than 50% of TPO-treated UT-7/GMT cells positively stained for Hb. Using UT-7/GMT cells, we examined how TPO promotes hemoglobinization. TPO induced tyrosine phosphorylation of the TPO receptor but not the erythropoietin (EPO) receptor. There was no competition between TPO and EPO for binding to EPO receptor. These findings suggest that TPO has a direct effect on hemoglobinization via a specific receptor on UT-7/GMT cells. Isoelectric focusing demonstrated that TPO induced fetal and adult Hb synthesis, whereas EPO induced embryonic, fetal, and adult Hb synthesis. Thus, our data suggest that TPO has a distinct action on erythropoiesis.
- Published
- 1998
41. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
- Author
-
Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P, and Whiteside TL
- Subjects
- Animals, Carcinoma immunology, Carcinoma secondary, Carcinoma therapy, Cells, Cultured, Coculture Techniques, Cytotoxicity, Immunologic, Genes, Synthetic, Genetic Vectors genetics, Humans, Interferon-gamma biosynthesis, Interleukin-2 biosynthesis, Killer Cells, Natural immunology, Killer Cells, Natural transplantation, Leukemia Virus, Murine genetics, Liver Neoplasms immunology, Liver Neoplasms secondary, Liver Neoplasms therapy, Lymphocyte Activation, Lymphoma, Non-Hodgkin pathology, Mice, Mice, Inbred BALB C, Mice, Nude, Phenotype, RNA, Messenger biosynthesis, Recombinant Fusion Proteins biosynthesis, Stomach Neoplasms pathology, Transfection, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha biosynthesis, Immunotherapy, Adoptive, Interleukin-2 genetics, Killer Cells, Natural metabolism
- Abstract
A variety of strategies have been attempted in the past to stably transduce natural killer (NK) cells with cytokine or other cellular genes. Here, we demonstrate the successful delivery of the interleukin-2 (IL-2) gene into two human NK cell lines, IL-2-dependent NK-92 and IL-2-independent YT, by retroviral transduction. An MuLV-based retroviral vector expressing human IL-2 and neor markers from a polycistronic message was constructed and transduced into a CRIP packaging cell line. By coincubation of NK cells with monolayers of CRIP cells or by using retrovirus-containing supernatants in a flow-through method, 10% to 20% of NK cells were stably transduced. Upon selection in the presence of increasing G418 concentrations, transduced NK cells were able to proliferate independently of IL-2 for more than 5 months and to secrete up to 5.5 ng/10(6) cells/24 h of IL-2. IL-2 gene-transduced NK-92 cells had an in vitro cytotoxicity against tumor targets that was significantly higher than that of parental cells and secreted interferon gamma (IFNgamma) and tumor necrosis factor alpha (TNFalpha) in addition to IL-2. Moreover, the in vivo antitumor activity of IL-2 gene-transduced NK-92 cells against established 3-day liver metastases in mice was greater than that of parental nontransduced NK cells. Stable expression of the IL-2 transgene in NK cells improved their therapeutic potential in tumor-bearing hosts. Thus, transduced NK cells secreted sufficient quantities of bioactive IL-2 to proliferate in vitro and mediated the antitumor effects both in vitro and in vivo in the absence of exogenous IL-2. These results suggest that genetic modification of NK cells ex vivo could be useful for clinical cancer therapy in the future.
- Published
- 1998
42. Molecular analysis of the IL-2 receptor beta chain gene expressed in human tumor cells.
- Author
-
Suminami Y, Kashii Y, Law JC, Lin WC, Stanson J, Reichert TE, Rabinowich H, and Whiteside TL
- Subjects
- Carcinoma, Renal Cell, DNA Primers, Head and Neck Neoplasms, Humans, Janus Kinase 1, Jurkat Cells, Kidney Neoplasms, Lymphocytes enzymology, Lymphocytes immunology, Macromolecular Substances, Neoplasms genetics, Oligonucleotides, Antisense, Polymerase Chain Reaction, Protein-Tyrosine Kinases biosynthesis, RNA, Messenger biosynthesis, Receptors, Interleukin-2 chemistry, Stomach Neoplasms, Transcription, Genetic, Tumor Cells, Cultured, Neoplasms immunology, Receptors, Interleukin-2 biosynthesis, Receptors, Interleukin-2 genetics
- Abstract
Interleukin-2 (IL-2) is recognized as a T cell growth factor. We have previously reported that human carcinoma cell lines are inhibited in growth by exogenous IL-2, which binds to the IL-2 receptor beta (IL-2Rbeta) chain ubiquitously expressed on the surface of tumor cells. A possibility was considered that IL-2Rbeta on carcinomas responsible for negative signaling was different from that expressed on hematopoietic cells. To investigate this possibility, mRNA for the IL-2Rbeta chain was amplified and compared in carcinoma and lymphoid cells. Using RT-PCR with pairs of sense-antisense oligonucleotide primers specific for the various regions of extracellular, transmembrane and intracellular domains of the IL-2Rbeta chain, we amplified mRNA obtained from three human carcinoma cell lines and human lymphoid cells as controls. The identity of the amplicons was confirmed by Southern analysis with the 32P-labeled cDNA probe coding for the entire span of the IL-2Rbeta chain. In addition, genomic DNA obtained from the tumor cell lines was sequenced to examine the possibility that a mutation is present in the gene coding for the intracellular IL-2Rbeta chain domain. No mutations or deletions were detected. The message for all three domains of the beta chain was identical in tumor cells and in normal lymphoid cells used as controls. Also, by Western blot and northern analyses no differences between IL-2Rbeta chain in tumors vs that expressed in lymphoid cells were demonstrable. The IL-2Rgamma chain, which participates in IL-2/IL-2R signaling pathway, was expressed in tumor cells. Expression of JAK1 transcripts in these cells was comparable to that in lymphocytes. However, RT-PCR analysis identified differences in expression of JAK3 splice variants (B and M) in tumor cells. These differences may be responsible for altered downstream signaling by IL-2. Overall, our data indicate that the same IL-2/IL-2R pathway is operative in human carcinomas and in normal epithelial or lymphoid cells.
- Published
- 1998
- Full Text
- View/download PDF
43. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
- Author
-
Nagashima S, Reichert TE, Kashii Y, Suminami Y, Chikamatsu K, and Whiteside TL
- Subjects
- Animals, Carcinoma, Squamous Cell therapy, Cell Division, Cell Line, Granulocyte-Macrophage Colony-Stimulating Factor biosynthesis, Head and Neck Neoplasms therapy, Humans, Interleukins biosynthesis, Kinetics, Mice, Mice, Nude, RNA, Messenger biosynthesis, Recombinant Proteins biosynthesis, Transcription, Genetic, Transfection methods, Transforming Growth Factor beta biosynthesis, Transplantation, Heterologous, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha biosynthesis, Carcinoma, Squamous Cell immunology, Carcinoma, Squamous Cell pathology, Cytotoxicity, Immunologic, Head and Neck Neoplasms immunology, Head and Neck Neoplasms pathology, Interleukin-2 biosynthesis, Killer Cells, Natural immunology
- Abstract
Two human squamous cell carcinoma of the head and neck (SCCHN) cell lines, PCI-13 and PCI-52, were transduced with the retroviral construct containing human interleukin-2 (IL-2) cDNA and selected for neomycin resistance in G418 medium. Stably transduced SCCHN cells produced and secreted IL-2, which was shown to have biologic activity in a bioassay, using an IL-2-dependent CTLL-2 cell line. By immunohistochemistry, IL-2 gene-transduced PCI-13 cells were strongly positive for IL-2, and by flow cytometry showed both cell surface and intracytoplasmic expression of IL-2 protein. Expression of IL-2 mRNA was measured by quantitative RT-PCR and found to be considerably increased in transduced SCCHN relative to that in parental cells. There was no difference in expression of IL-2R between the parental and IL-2 gene-transduced cells. In vitro proliferation of IL-2 gene-transduced tumor cells was consistently more rapid than that of parental cells. Sensitivity of the parental and IL-2 gene-transduced targets to lysis or apoptosis mediated by purified human natural killer (NK) cells or IL-2-activated NK (A-NK) cells was comparable as measured in 4-hour 51Cr-release and 1-hour [3H]thymidine-release assays, respectively. However, transduced cells were significantly more sensitive than parental cells to these effectors in 24-hour MTT assays, most likely due to IL-2 production by the transduced targets. PCI-52 cells selected for in vivo experiments formed large subcutaneous tumors in immunosuppressed nude mice. Tumors established by subcutaneous injections of 1 x 10(7) IL-2 gene-transduced cells regressed completely by day 25, while those formed by parental or LacZ gene-transduced tumor cells grew progressively. Tumor regression was mediated by numerous mononuclear cells, identified as murine NK cells and macrophages by immunohistochemistry, which accumulated around the IL-2-secreting, but not parental, tumors within 5-6 days after tumor cell injections. Thus, IL-2 gene-transduced SCCHN cells produce functional IL-2 in vivo in amounts sufficient to support the recruitment to the tumor site and antitumor activity of cytotoxic effector cells. IL-2-secreting SCCHN cells may be a useful component of vaccines designed to induce and sustain effector cell activation at the tumor site.
- Published
- 1997
44. Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo.
- Author
-
Nagashima S, Kashii Y, Reichert TE, Suminami Y, Suzuki T, and Whiteside TL
- Subjects
- Animals, Cell Division, Cytotoxicity Tests, Immunologic, Humans, Interleukin-2 biosynthesis, Killer Cells, Natural immunology, Liver Neoplasms pathology, Liver Neoplasms secondary, Mice, Mice, Nude, Neoplasm Transplantation, RNA, Messenger metabolism, Stomach Neoplasms immunology, Stomach Neoplasms mortality, Transduction, Genetic, Tumor Cells, Cultured, Interleukin-2 genetics, Stomach Neoplasms genetics
- Abstract
We transduced a human gastric carcinoma cell line, HR, with the interleukin 2 (IL-2) gene. Stable HR transfectants secreted nanogram quantities of biologically active IL-2 and had significantly increased expression of IL-2 mRNA relative to that in parental cells. Expression of intracellular IL-2 protein was not quantitatively different in the parental and IL-2 gene-transduced cells, although the former did not secrete IL-2. Surface expression of IL-2 receptors was comparable in the parental and transduced cells at the mRNA or protein levels. Nevertheless, in vitro proliferation of IL-2 gene-transduced HR cells was significantly more rapid than that of parental cells. Both parental and IL-2 gene-transduced HR cells were equally sensitive to lysis by IL-2-activated natural killer (A-NK) cells, as measured in 4 hr 51Cr-release assasys or to apoptosis induced by NK or A-NK cells, assessed in 1 hr 3H-TdR-release assays. In 24 hr MTT assays, however, the IL-2 gene-transduced cells were significantly more sensitive to these effector cells than were parental cells. Upon intrasplenic injection of 5 x 10(6) parental or transduced HR cells into nude mice, liver metastases developed. Metastases of parental HR cells killed the animals in 24 days. In contrast, metastases of the IL-2 gene-transduced HR cells became necrotic by day 14 and were found to be surrounded by murine NK cells and macrophages. Survival of nude mice injected with IL-2 gene-transduced HR cells was significantly prolonged (>50 days) relative to that of mice injected with parental HR. Thus, IL-2 gene-transduced HR cells produced sufficient amounts of functional IL-2 in vivo to be able to recruit to the tumor site and support functions of endogenous cytotoxic immune effector cells, which were responsible for regression of hepatic metastases and significant improvement of survival in these mice.
- Published
- 1997
- Full Text
- View/download PDF
45. Clonal accumulation of V beta 5.1-positive cells in the liver of a patient with autoimmune cholangiopathy.
- Author
-
Shimizu Y, Higuchi K, Kashii Y, Miyamoto M, Tsukishiro T, and Watanabe A
- Subjects
- Adult, Antibodies, Antinuclear metabolism, Biopsy, Female, Hepatitis immunology, Humans, Immunoglobulin G metabolism, Immunoglobulin M metabolism, Immunohistochemistry, Liver Cirrhosis, Biliary immunology, Prednisone therapeutic use, Ursodeoxycholic Acid therapeutic use, Autoimmune Diseases immunology, Cholangitis immunology, Liver immunology, Receptors, Antigen, T-Cell, alpha-beta metabolism, T-Lymphocytes metabolism
- Abstract
We describe a 43-year-old woman with clinical features compatible with autoimmune cholangiopathy recently reported by Ben Ari et al. She was negative for anti-mitochondrial antibody, positive for high titer anti-nuclear antibody with homogeneous pattern, high levels of serum immunoglobulin G and nearly normal levels of serum immunoglobulin M for more than five years. In the early stages of the disease, the elevations of serum transaminase, alkaline phosphatase and gamma-glutamyl transpeptidase were well controlled by the administration of ursodeoxycholic acid. After five years of follow-up, she showed the second exacerbation of liver function tests, which then rapidly improved by prednisone administration. To analyze the antigen diversity recognized by T-cells in the liver, T-cell receptor repertoire was examined by immuno-histochemistry. The liver biopsy obtained in the early stage showed clonal accumulation of V beta 5.1-positive cells in portal areas, which was found in patients neither with primary biliary cirrhosis nor autoimmune hepatitis. In conclusion, these data suggest that T-cell response in autoimmune cholangiopathy is different from those two autoimmune liver diseases, which may imply a distinct entity of the disease.
- Published
- 1997
- Full Text
- View/download PDF
46. [Analyses of T-cell receptor repertoire in liver-infiltrating lymphocytes in chronic hepatitis B using PCR method].
- Author
-
Kashii Y, Shimizu Y, Nambu S, and Watanabe A
- Subjects
- Humans, Polymerase Chain Reaction, Hepatitis B, Chronic, Lymphocytes chemistry, Receptors, Antigen, T-Cell, alpha-beta
- Published
- 1995
47. [Analyses of T-cell receptor repertoire in liver-infiltrating lymphocytes in chronic hepatitis C using immunohistochemical and PCR methods].
- Author
-
Kashii Y, Shimizu Y, Nambu S, and Watanabe A
- Subjects
- Chronic Disease, Humans, Immunohistochemistry, Polymerase Chain Reaction, Hepatitis C immunology, Liver pathology, Lymphocytes immunology, Lymphocytes pathology, Receptors, Antigen, T-Cell, alpha-beta analysis
- Published
- 1995
48. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis.
- Author
-
Shimizu Y, Minemura M, Tsukishiro T, Kashii Y, Miyamoto M, Nishimori H, Higuchi K, and Watanabe A
- Subjects
- Adult, Aged, Antigens, CD blood, CD58 Antigens, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Enzyme-Linked Immunosorbent Assay, Female, Humans, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Membrane Glycoproteins blood, Middle Aged, Neoplasm Staging, Prognosis, Survival Rate, Carcinoma, Hepatocellular blood, Intercellular Adhesion Molecule-1 blood, Liver Neoplasms blood
- Abstract
Serum levels of soluble forms of intracellular adhesion molecule-1 (sICAM-1) and lymphocyte function-associated antigen-3 (sLFA-3) in 122 patients with chronic liver disease including hepatocellular carcinoma (HCC) were measured by enzyme-linked immunosorbent assays. Serum levels of sICAM-1 in patients with HCC were significantly higher than those of chronic hepatitis (CH) and cirrhosis. On the other hand, serum levels of sLFA-3 in patients with HCC were almost the same as those of cirrhosis. Western blot analyses showed that molecular sizes of sICAM-1 and sLFA-3 detected in the sera were 90 kd and 50 kd, respectively, indicating that both molecules include whole extracellular domains. In patients with HCC, circulating sICAM-1 levels were significantly (P < .001) correlated with tumor volume (r = .50), total bilirubin (r = .38), serum aspartate aminotransferase levels (r = .51), and gamma-globulin (r = .63). Furthermore, serum sICAM-1 levels were significantly elevated in patients with multiple HCC (tumor number > 3) or HCC with tumor embolus in the first branch or trunk of portal vein. Survival periods were analyzed in relation to serum sICAM-1 levels in patients with HCC who had been treated by transcatheter arterial chemoembolization. The HCC patients with < 1,000 ng/mL of serum ICAM-1 showed significantly (P = .0005) longer survival than those with higher levels of the molecule. The same results were obtained when only patients with moderately differentiated HCC were analyzed (P = .02). Analyses by Cox's proportional hazard model showed that sICAM-1 is a significant (P = .032) prognostic factor for patients with HCC.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1995
49. [A familial case of DRPLA diagnosed by an autopsy associated with hemoglobinopathy (Hb Takamatsu)].
- Author
-
Sakata T, Murata A, Kashii Y, Tamagaki C, Watanabe S, and Saito M
- Subjects
- Atrophy, Female, Hemoglobinopathies blood, Humans, Middle Aged, Brain pathology, Cerebellar Nuclei pathology, Globus Pallidus pathology, Hemoglobinopathies complications, Hemoglobins, Abnormal metabolism, Red Nucleus pathology
- Abstract
The patient first noticed general muscle stiffness at the age of 36. Two years later, she suffered from a tonic-clonic seizure which brought her to a hospital for the first time. Choreoathetoid movement, ataxia and cognitive deficit were apparent. At the age of 44, tonic-clonic seizures became more frequent and she was admitted to our hospital as being status epilepticus. After the cessation of clinical seizures, she became appllic. Gradual increase of atrophic changes in cerebrum, cerebellum and brain stem were observed by MRI and CT. Hematological study showed that she had abnormal hemoglobin, Hb Takamatsu. Four of her five children were clinically examined; all of them showed abnormal EEG findings; three being mentally retarded and had clinical generalized convulsive seizures; two had hemoglobinopathy (Hb Takamatsu). The patient died from sepsis at the age of 50 and the autopsy was carried out. The brain weighed 930 gram. Histological findings confirmed the diagnosis of dentato-rubro-pallido-luysian atrophy; neuronal loss accompanied by gliosis in dentate nuclei, red nuclei, lateral part of globus pallidus, and subthalamic nuclei. The coincidence of the hereditary traits of two independent diseases, DRPLA and familial hemoglobinopathy (Hb Takamatsu) suggests closeness of their genetic loci.
- Published
- 1993
50. [A case of presenile dementia with peculiar speech-- palilalia].
- Author
-
Kashii Y, Watanabe S, Kitashiro M, Saito A, Murata A, Yuri K, Saito M, and Tsuda T
- Subjects
- Female, Humans, Middle Aged, Dementia complications, Speech Disorders etiology
- Published
- 1990
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.